Subsequently, a growing number of MMP-2/9 inhibitors are being developed as anti-metastatic agent; Fucoidan, an anti-metastatic agent, significantly reduces lung cancer cell migration and invasion by down-regulating the levels of MMP-2 via the suppression of PI3K-Akt-mTOR and NF-kB signalling pathway [39]. This evidence concerns the gene NFKB1 and lung carcinoma.